BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology 2010;35:1464-76. [PMID: 20200509 DOI: 10.1038/npp.2010.16] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Kalyanasundar B, Perez CI, Arroyo B, Moreno MG, Gutierrez R. The Appetite Suppressant D-norpseudoephedrine (Cathine) Acts via D1/D2-Like Dopamine Receptors in the Nucleus Accumbens Shell. Front Neurosci 2020;14:572328. [PMID: 33177980 DOI: 10.3389/fnins.2020.572328] [Reference Citation Analysis]
2 Zvejniece L, Svalbe B, Vavers E, Makrecka-Kuka M, Makarova E, Liepins V, Kalvinsh I, Liepinsh E, Dambrova M. S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity. Pharmacol Biochem Behav 2017;160:21-9. [PMID: 28743458 DOI: 10.1016/j.pbb.2017.07.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
3 Greydanus DE, Agana M, Kamboj MK, Shebrain S, Soares N, Eke R, Patel DR. Pediatric obesity: Current concepts. Disease-a-Month 2018;64:98-156. [DOI: 10.1016/j.disamonth.2017.12.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
4 Tsilingiris D, Liatis S, Dalamaga M, Kokkinos A. The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications. Curr Obes Rep 2020;9:136-49. [PMID: 32388792 DOI: 10.1007/s13679-020-00378-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Appel L, Bergström M, Buus Lassen J, Långström B. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur Neuropsychopharmacol 2014;24:251-61. [PMID: 24239329 DOI: 10.1016/j.euroneuro.2013.10.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
6 Fulenwider HD, Robins MT, Caruso MA, Ryabinin AE. Social Housing Leads to Increased Ethanol Intake in Male Mice Housed in Environmentally Enriched Cages. Front Behav Neurosci 2021;15:695409. [PMID: 34220465 DOI: 10.3389/fnbeh.2021.695409] [Reference Citation Analysis]
7 Narayanaswami V, Dwoskin LP. Obesity: Current and potential pharmacotherapeutics and targets. Pharmacol Ther 2017;170:116-47. [PMID: 27773782 DOI: 10.1016/j.pharmthera.2016.10.015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 11.5] [Reference Citation Analysis]
8 Sjödin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, Meier D, Astrup A. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010;34:1634-1643. [PMID: 20479765 DOI: 10.1038/ijo.2010.87] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
9 Dalbøge LS, Pedersen SL, van Witteloostuijn SB, Rasmussen JE, Rigbolt KTG, Jensen KJ, Holst B, Vrang N, Jelsing J. Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake: LIPIDATED NMU ANALOGS DECREASE ACUTE FOOD INTAKE IN MICE. J Pept Sci 2015;21:85-94. [DOI: 10.1002/psc.2727] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
10 Tran P, Skolnick P, Czobor P, Huang N, Bradshaw M, Mckinney A, Fava M. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research 2012;46:64-71. [DOI: 10.1016/j.jpsychires.2011.09.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 5.5] [Reference Citation Analysis]
11 Glastras SJ, Valvi D, Bansal A. Editorial: Developmental Programming of Metabolic Diseases. Front Endocrinol (Lausanne) 2021;12:781361. [PMID: 34745018 DOI: 10.3389/fendo.2021.781361] [Reference Citation Analysis]
12 van Witteloostuijn SB, Mannerstedt K, Wismann P, Bech EM, Thygesen MB, Vrang N, Jelsing J, Jensen KJ, Pedersen SL. Neoglycolipids for Prolonging the Effects of Peptides: Self-Assembling Glucagon-like Peptide 1 Analogues with Albumin Binding Properties and Potent in Vivo Efficacy. Mol Pharmaceutics 2017;14:193-205. [DOI: 10.1021/acs.molpharmaceut.6b00787] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
13 Comley RA, Salinas CA, Slifstein M, Petrone M, Marzano C, Bennacef I, Shotbolt P, Van der Aart J, Neve M, Iavarone L, Gomeni R, Laruelle M, Gray FA, Gunn RN, Rabiner EA. Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther 2013;346:311-7. [PMID: 23685546 DOI: 10.1124/jpet.112.202895] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
14 Kintscher U. Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin. In: Joost H, editor. Appetite Control. Berlin: Springer Berlin Heidelberg; 2012. pp. 339-47. [DOI: 10.1007/978-3-642-24716-3_15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
15 Tan Q, Orsso CE, Deehan EC, Triador L, Field CJ, Tun HM, Han JC, Müller TD, Haqq AM. Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review. Obes Rev 2020;21:e12992. [PMID: 31889409 DOI: 10.1111/obr.12992] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
16 van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, Booij J. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. European Neuropsychopharmacology 2012;22:290-9. [DOI: 10.1016/j.euroneuro.2011.07.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
17 Rosa-Gonçalves P, Majerowicz D. Pharmacotherapy of Obesity: Limits and Perspectives. Am J Cardiovasc Drugs 2019;19:349-64. [PMID: 30793263 DOI: 10.1007/s40256-019-00328-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
18 Gragnoli C, Reeves GM, Reazer J, Postolache TT. Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity. Transl Psychiatry 2016;6:e785. [PMID: 27093067 DOI: 10.1038/tp.2016.50] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
19 Nikolic D, Toth PP, Ferlita A, Bartolo VD, Montalto G, Banach M, Rizzo M. Novel anti-obesity drugs and plasma lipids. Clinical Lipidology 2014;9:179-87. [DOI: 10.2217/clp.14.7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
20 Moradi S, Alivand M, Khajebishak Y, Asgharijafarabadi M, Alipour M, Chilibeck PD, Alipour B. The effect of short-term omega-3 fatty acids supplementation on appetite in healthy men: A randomized double-blinded controlled clinical trial. Nutrition Clinique et Métabolisme 2022;36:46-53. [DOI: 10.1016/j.nupar.2021.08.004] [Reference Citation Analysis]
21 Ratner C, Ettrup A, Bueter M, Haahr ME, Compan V, le Roux CW, Levin B, Hansen HH, Knudsen GM. Cerebral markers of the serotonergic system in rat models of obesity and after Roux-en-Y gastric bypass. Obesity (Silver Spring) 2012;20:2133-41. [PMID: 22450706 DOI: 10.1038/oby.2012.75] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
22 Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS. Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. Endocr Rev 2021:bnab034. [PMID: 34698815 DOI: 10.1210/endrev/bnab034] [Reference Citation Analysis]
23 Coulter AA, Rebello CJ, Greenway FL. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs 2018;78:1113-32. [PMID: 30014268 DOI: 10.1007/s40265-018-0946-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 12.7] [Reference Citation Analysis]
24 Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, Strømgaard K, Gether U. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 2011;63:585-640. [PMID: 21752877 DOI: 10.1124/pr.108.000869] [Cited by in Crossref: 509] [Cited by in F6Publishing: 473] [Article Influence: 46.3] [Reference Citation Analysis]
25 Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring) 2013;21:985-92. [PMID: 23784901 DOI: 10.1002/oby.20122] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
26 van Witteloostuijn SB, Dalbøge LS, Hansen G, Midtgaard SR, Jensen GV, Jensen KJ, Vrang N, Jelsing J, Pedersen SL. GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice: SCT/GLP-1 Co-agonist Decreases Food Intake and Preserves Beta Cell Mass. J Pept Sci 2017;23:845-54. [DOI: 10.1002/psc.3048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
27 Hansen HH, Jensen MM, Overgaard A, Weikop P, Mikkelsen JD. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacology Biochemistry and Behavior 2013;110:265-71. [DOI: 10.1016/j.pbb.2013.07.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
28 Serafine KM, O'Dell LE, Zorrilla EP. Converging vulnerability factors for compulsive food and drug use. Neuropharmacology 2021;196:108556. [PMID: 33862029 DOI: 10.1016/j.neuropharm.2021.108556] [Reference Citation Analysis]
29 Gilbert JA, Gasteyger C, Raben A, Meier DH, Astrup A, Sjödin A. The effect of tesofensine on appetite sensations. Obesity (Silver Spring). 2012;20:553-561. [PMID: 21720440 DOI: 10.1038/oby.2011.197] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
30 Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA. Serotonergic anti-obesity agents: past experience and future prospects. Drugs 2011;71:2247-55. [PMID: 22085383 DOI: 10.2165/11596680-000000000-00000] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]